Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Galenica AG ( (CH:GALE) ) has provided an announcement.
Galenica AG reported a 4.7% increase in sales to CHF 2,999.7 million by the third quarter of 2025, driven by prescription drugs and nutritional supplements. The acquisition of Labor Team is expected to boost sales growth to between 4% and 6% and EBIT1 increase to between 10% and 12%. Despite a competitive consumer healthcare market, Galenica has maintained its market position, with significant contributions from its ‘Products & Care’ and ‘Logistics & IT’ segments.
The most recent analyst rating on (CH:GALE) stock is a Hold with a CHF93.00 price target. To see the full list of analyst forecasts on Galenica AG stock, see the CH:GALE Stock Forecast page.
More about Galenica AG
Galenica AG is a Swiss company operating in the healthcare sector, with a focus on pharmacies, pharmaceutical logistics, and home care services. It is listed on the Swiss stock exchange and employs approximately 8,000 people, aiming to meet the needs of customers and patients in the Swiss healthcare market.
Average Trading Volume: 78,100
Technical Sentiment Signal: Buy
Current Market Cap: CHF4.42B
Find detailed analytics on GALE stock on TipRanks’ Stock Analysis page.
Trending Articles:
- RTO Doesn’t Always Mean RTO: Microsoft Stock (NASDAQ:MSFT) Notches Up as Salespeople Find Exemption
- This Was Not the First Bid: Warner Bros. Discovery Stock (NASDAQ:WBD) Gains as it Rejected Three Bids from Paramount So Far
- ‘Paramount Can Walk Away with Warner Bros.’ Say TD Cowen and Benchmark Analysts